Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

About Acalabrutinib API

Product
  • Categoría Terapéutica Oncology

  • Número CAS

    870524-78-5

  • Tecnología del API

    Molécula pequeña

  • Forma de Dosificación

    Sólido Oral/Cápsulas

  • Estado de Desarrollo en Dr. Reddy’s

    En desarrollo

Mechanism of Action

Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays an important role in the survival and growth of B cells. By blocking BTK, acalabrutinib can help to slow down or even stop the growth of cancer cells.

Indication

The FDA approved Acalabrutinib for the treatment of adult patients with Mantle Cell Lymphoma (MCL) has received at least one prior therapy. Chronic lymphocytic leukemia (CLL). Small lymphocytic lymphoma (SLL).

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Acalabrutinib
Select Regulatory Requirements
Select Purpose

Related APIs

Ácido Zoledrónico

Oncology

arrow

Dasatinib

Oncology

arrow

Adagrasib

Oncology

arrow

Clorhidrato De Bendamustina

Oncology

arrow

Fruquintinib

Oncology

arrow

Venetoclax

Oncology

arrow

Tucatinib

Oncology

arrow

Ripretinib

Oncology

arrow

Acetato De Abiraterona

Oncology

arrow

Azacitidina

Oncology

arrow

Bortezomib

Oncology

arrow

Cabazitaxel

Oncology

arrow

Cabozantinib HCl

Oncology

arrow

Cabozantinib S-Malate

Oncology

arrow

Capecitabina

Oncology

arrow

Carfilzomib

Oncology

arrow

Decitabina

Oncology

arrow

Deucravacitinib

Oncology

arrow

Apalutamide (Amorphous & Form B)

Oncology

arrow

Mesilato De Eribulina

Oncology

arrow

Gemcitabine Hydrochloride

Oncology

arrow

Lomustina

Oncology

arrow

Nilotinib Clorhidrato

Oncology

arrow

Olaparib (Form A)

Oncology

arrow

Palbociclib

Oncology

arrow

Pazopanib

Oncology

arrow

Pemetrexed Disodium (Heptahidrato)

Oncology

arrow

Pirtobrutinib

Oncology

arrow

Relugolix

Oncology

arrow

Pomalidomida

Oncology

arrow

Acalabrutinib

Oncology

arrow

Capivasertib

Oncology

arrow

Lenalidomida (Form A)

Oncology

arrow

Midostaurina(Amorphous and Form II)

Oncology

arrow

Lenvatinib Mesylate (Form C and MIBK Solvate)

Oncology

arrow

Enzalutamida (Crystalline & Premix)

Oncology

arrow

Descargo de responsabilidad

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.